Single-arm P2 study | Toxic effects of stereotactic ablative radiotherapy for up to 5 oligometastases in patients with cancer.

Treatment With Stereotactic Ablative Radiotherapy for Up to 5 Oligometastases in Patients With Cancer: Primary Toxic Effect Results of the Nonrandomized Phase 2 SABR-5 Clinical Trial – JAMA Oncology (link to abstract – $ for full-text)

Commentary: Stereotactic Ablative Body Radiotherapy Produces Acceptable Toxic Effects in Patients With Cancer and Oligometastses – Cancer Network

Commentary on Twitter

Population-based phase 2 non-randomized trial of 381 pts w/oligometastatic or oligoprogressive disease & treated w/stereotactic ablative body radiotherapy (SABR) found rates of grade 2, 3,4, & 5 toxicities of 14.2%, 4.2%, 0%, & 0.3%, respectively. https://t.co/dDpdOEvNzk #RadOnc

— JAMA Oncology (@JAMAOnc) September 29, 2022